Regeneron Pharmaceuticals (REGN) Set to Announce Earnings on Thursday

Regeneron Pharmaceuticals (NASDAQ:REGN) will release its earnings data before the market opens on Thursday, October 31st. Analysts expect Regeneron Pharmaceuticals to post earnings of $10.04 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the firm earned $8.79 earnings per share. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts expect Regeneron Pharmaceuticals to post $38 EPS for the current fiscal year and $40 EPS for the next fiscal year.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $927.33 on Wednesday. Regeneron Pharmaceuticals has a fifty-two week low of $772.84 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock has a market capitalization of $102.23 billion, a P/E ratio of 24.56, a P/E/G ratio of 3.20 and a beta of 0.12. The business has a 50-day moving average of $1,077.78 and a two-hundred day moving average of $1,041.48.

Wall Street Analyst Weigh In

REGN has been the subject of several research analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $1,260.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 22nd. Piper Sandler boosted their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Finally, StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,101.00.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.